{"id":32931,"date":"2025-05-07T09:58:32","date_gmt":"2025-05-07T01:58:32","guid":{"rendered":"https:\/\/flcube.com\/?p=32931"},"modified":"2025-05-07T09:58:33","modified_gmt":"2025-05-07T01:58:33","slug":"everest-medicines-nefecon-receives-full-approval-from-nmpa-for-igan-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32931","title":{"rendered":"Everest Medicines’ Nefecon Receives Full Approval from NMPA for IgAN Treatment"},"content":{"rendered":"\n

China-based Everest Medicines (HKG: 1952<\/a>) announced that the National Medical Products Administration (NMPA) has converted the conditional approval to complete approval for its Nefecon (targeted-release budesonide) as a treatment for adult primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. This full approval lifts the restriction on proteinuria levels and makes Nefecon the first and only etiological treatment for the condition in China.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
The NMPA’s decision is based on the final complete data from the Phase III Nef Ig Ard study, a randomized, double-blinded, multi-center study assessing the efficacy and safety of Nefecon (16 mg, once daily) in adult patients with primary IgAN receiving optimized RAS inhibitor therapy. The study lasted for 2 years, including a 9-month treatment period with Nefecon or placebo, followed by a 15-month follow-up period after discontinuation of medication. Global results show that compared to placebo, Nefecon not only brings persistent proteinuria reduction and reduces the risk of microscopic hematuria but also shows clinical significance and statistical differences (P<0.0001) in estimating glomerular filtration rate (eGFR), reducing renal function decline by up to 50%. Data in the Chinese population shows that Nefecon can delay renal function decline by up to 66% and is expected to delay the progression of the disease to dialysis or kidney transplantation by 12.8 years.<\/p>\n\n\n\n

Licensing and Market Expansion<\/strong>
In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas, giving Everest exclusive rights to develop and commercialize Nefecon in Mainland China, Hong Kong, Macau, Taiwan, and Singapore. That deal was expanded to include South Korea in March 2022. Nefecon was conditionally approved for marketing in November 2023 in China to treat primary IgAN in adults at risk of disease progression, followed by marketing nods in South Korea, Singapore, Hong Kong, and Taiwan.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted…<\/p>\n","protected":false},"author":1,"featured_media":32932,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[126,1164,15],"class_list":["post-32931","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-everest-medicines","tag-hkg-1952","tag-product-approvals"],"yoast_head":"\nEverest Medicines' Nefecon Receives Full Approval from NMPA for IgAN Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted the conditional approval to complete approval for its Nefecon (targeted-release budesonide) as a treatment for adult primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. This full approval lifts the restriction on proteinuria levels and makes Nefecon the first and only etiological treatment for the condition in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32931\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines' Nefecon Receives Full Approval from NMPA for IgAN Treatment\" \/>\n<meta property=\"og:description\" content=\"China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted the conditional approval to complete approval for its Nefecon (targeted-release budesonide) as a treatment for adult primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. This full approval lifts the restriction on proteinuria levels and makes Nefecon the first and only etiological treatment for the condition in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32931\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-07T01:58:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-07T01:58:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0701.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32931#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32931\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines’ Nefecon Receives Full Approval from NMPA for IgAN Treatment\",\"datePublished\":\"2025-05-07T01:58:32+00:00\",\"dateModified\":\"2025-05-07T01:58:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32931\"},\"wordCount\":305,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32931#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0701.webp\",\"keywords\":[\"Everest Medicines\",\"HKG: 1952\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32931#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32931\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32931\",\"name\":\"Everest Medicines' Nefecon Receives Full Approval from NMPA for IgAN Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32931#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32931#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0701.webp\",\"datePublished\":\"2025-05-07T01:58:32+00:00\",\"dateModified\":\"2025-05-07T01:58:33+00:00\",\"description\":\"China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted the conditional approval to complete approval for its Nefecon (targeted-release budesonide) as a treatment for adult primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. This full approval lifts the restriction on proteinuria levels and makes Nefecon the first and only etiological treatment for the condition in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32931#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32931\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32931#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0701.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0701.webp\",\"width\":1080,\"height\":608,\"caption\":\"Everest Medicines' Nefecon Receives Full Approval from NMPA for IgAN Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32931#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines’ Nefecon Receives Full Approval from NMPA for IgAN Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines' Nefecon Receives Full Approval from NMPA for IgAN Treatment - Insight, China's Pharmaceutical Industry","description":"China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted the conditional approval to complete approval for its Nefecon (targeted-release budesonide) as a treatment for adult primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. This full approval lifts the restriction on proteinuria levels and makes Nefecon the first and only etiological treatment for the condition in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32931","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines' Nefecon Receives Full Approval from NMPA for IgAN Treatment","og_description":"China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted the conditional approval to complete approval for its Nefecon (targeted-release budesonide) as a treatment for adult primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. This full approval lifts the restriction on proteinuria levels and makes Nefecon the first and only etiological treatment for the condition in China.","og_url":"https:\/\/flcube.com\/?p=32931","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-07T01:58:32+00:00","article_modified_time":"2025-05-07T01:58:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0701.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32931#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32931"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines’ Nefecon Receives Full Approval from NMPA for IgAN Treatment","datePublished":"2025-05-07T01:58:32+00:00","dateModified":"2025-05-07T01:58:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32931"},"wordCount":305,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32931#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0701.webp","keywords":["Everest Medicines","HKG: 1952","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32931#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32931","url":"https:\/\/flcube.com\/?p=32931","name":"Everest Medicines' Nefecon Receives Full Approval from NMPA for IgAN Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32931#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32931#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0701.webp","datePublished":"2025-05-07T01:58:32+00:00","dateModified":"2025-05-07T01:58:33+00:00","description":"China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted the conditional approval to complete approval for its Nefecon (targeted-release budesonide) as a treatment for adult primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. This full approval lifts the restriction on proteinuria levels and makes Nefecon the first and only etiological treatment for the condition in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32931#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32931"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32931#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0701.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0701.webp","width":1080,"height":608,"caption":"Everest Medicines' Nefecon Receives Full Approval from NMPA for IgAN Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32931#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines’ Nefecon Receives Full Approval from NMPA for IgAN Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0701.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32931"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32931\/revisions"}],"predecessor-version":[{"id":32933,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32931\/revisions\/32933"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32932"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32931"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}